Clinical trials: APL
Leukemia, Promyelocytic, Acute
Acute Promyelocytic Leukemia 2006 (APL)
To assess the role of Arsenic trioxide and/or ATRA during consolidation course in APL. It is hoped that the investigational arms will further increase the event-free survival at 2 years, with reduced toxicity and without…
- Trial name
- NCT00378365
- Testing
- Arsenic trioxide, ATRA
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia
Phase III Trial in Acute Promyelocytic Leukemia Patients
Open label, randomised, phase III multicenter trial.
- Trial name
- APL0406 (NCT00482833)
- Testing
- arsenic trioxide, idarubicin, mercaptopurine
- Where
- 110 sites in Austria, Germany and 1 more
- Volunteers
- 276 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloproliferative Disorders, Leukemia
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00293410
- Testing
- clofarabine, cyclophosphamide
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematologic Neoplasms, Bone Marrow Neoplasms
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.
- Conditions
- Hematologic Neoplasms, Bone Marrow Neoplasms, Non-Hodgkin's Lymphoma
- Trial name
- NCT00421213
- Testing
- Darinaparsin
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alaunos Therapeutics
Acute Promyelocytic Leukemia (APL), Acute Myeloid Leukaemia (AML)
AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment
This study will test whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately.
- Trial name
- LEAP (NCT07203885)
- Testing
- Unaided Review First, Then AI-Assisted Review, AI-Assisted Review First, Then Unaided Review
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Leukemia, Promyelocytic, Acute
Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database
Acute promyelocytic leukemia (APL) is a very rare type of leukemia. Because it is so rare, many doctors do not have experience treating it. APL has been shown to be curable most of the time.
- Trial name
- NCT02309333
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- Emory University
Relapsed Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Summary Acute promyelocytic leukemia is defined by a characteristic morphology (AML FAB M3/M3v), by the specific translocation t(15;17) and its molecular correlates (PML/RARa and RARa/PML).
- Trial name
- NCT00196768
- Testing
- Arsenic trioxide, Trisenox
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- German AML Cooperative Group
Leukemia, Lymphoma
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003396
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Maryland, Baltimore
Adult Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia
This research study is studying biomarkers in patients with acute promyelocytic leukemia. Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and…
- Conditions
- Adult Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Childhood Acute Promyelocytic Leukemia (M3)
- Trial name
- NCT01146223
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Childhood Acute Promyelocytic Leukemia
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Outcome of acute promyelocytic leukemia (APL) has greatly improved since the introduction of all-trans-retinoic acid (ATRA). Treatment with ATRA and anthracycline-based chemotherapy (ATRA + chemotherapy) decreases relapses of the…
- Trial name
- NCT02200978
- Testing
- ATO, RIF, ATRA
- Where
- China
- Volunteers
- 176 people
- Sponsor
- South China Children's Leukemia Group
Leukemia, Lymphoma
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in treating…
- Trial name
- NCT00020111
- Testing
- arsenic trioxide
- Where
- 52 sites in United States, Australia and 1 more
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Kidney Cancer
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth. PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who…
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00036712
- Testing
- management of therapy complications, pain therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical College of Wisconsin
Leukemia
Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia
RATIONALE: Studying samples fo tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01232855
- Testing
- protein expression analysis, western blotting, flow cytometry
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation…
- Conditions
- Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Trial name
- LATITUDE (NCT07296445)
- Testing
- Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA)
- Volunteers
- 120 people
- Sponsor
- SDK Therapeutics, Inc.
Leukemia, Lung Cancer
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells.
- Conditions
- Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006019
- Testing
- azacitidine, sodium phenylbutyrate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Promyelocytic Leukemia (APL)
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
- Trial name
- NCT06882031
- Testing
- Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- SDK Therapeutics, Inc.
Leukemia, Myelodysplastic Syndromes
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help…
- Trial name
- NCT00844441
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 96 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy
This randomized pilot clinical trial studies a home telemonitoring device in managing the care of patients with myelodysplastic syndrome or acute myeloid leukemia after they are discharged from the hospital following…
- Trial name
- NCT02226497
- Testing
- Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
This 12 week study will observe patients with and without systemic lupus erythematosus who have persistent antiphospholipid antibodies in the blood who are starting a medicine called hydroxychloroquine.
- Conditions
- Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody, Systemic Lupus Erythematosus
- Trial name
- NCT01475149
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hospital for Special Surgery, New York